Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

By sjmartinez • September 19, 2023

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. PMID: 37592104.

Tags: Dermatology, Hematology/Oncology, Publications

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Chen HC, Bang MF, Wang HH, Shpargel KB, Kohn LA, Sailer D, Zhang S, McCarthy EC, Seyedsadr M, Stevens S, Pham CLH, Zhou Z, Yin[...]

Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses

Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025 Oct 18;24:172-176. doi: 10.1016/j.jdin.2025.10.004. PMID:[...]

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition

Johnsen NA, Carlisle R, Baghoomian W, Pierce JL, Nguyen MO. A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified[...]